Measurement of BNP or NT-proBNP is useful to support clinical judgment for the diagnosis of acutely decom- pensated HF, especially in the setting of uncertainty for the diagnosis (92 98). (Level of Evidence: A) Table 5. Selected Multivariable Risk Scores to Predict Outcome in HF Risk Score Reference/Link Chronic HF All patients with chronic HF Seattle Heart Failure Model (56) http://SeattleHeartFailureModel.org Heart Failure Survival Score (52) http://handheld.softpedia.com/get/Health/Calculator/HFSS-Calc-37354.shtml CHARM Risk Score (59) CORONA Risk Score (60) Specific to chronic HFpEF I-PRESERVE Score (54) Acutely decompensated HF ADHERE Classification and Regression Tree (CART) Model (53) American Heart Association Get With The Guidelines Score (58) http://www.heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/ GetWithTheGuidelinesHeartFailureHomePage/Get-With-The-Guidelines-Heart-Failure-Home- EFFECT Risk Score (55) http://www.ccort.ca/Research/CHFRiskModel.aspx ESCAPE Risk Model and Discharge Score (61) OPTIMIZE HF Risk-Prediction Nomogram (62) ADHERE indicates Acute Decompensated Heart Failure National Registry; CHARM, Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity; CORONA,ControlledRosuvastatinMultinationalTrial in HeartFailure;EFFECT,Enhanced Feedbackfor EffectiveCardiacTreatment;ESCAPE, Evaluation Studyof Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; I-PRESERVE, Irbesartan in Heart Failure with Preserved Ejection Fraction Study; and OPTIMIZE, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure. JACC Vol. 62, No. 16, 2013 Yancy et al. October 15, 2013:1495 539 2013 ACCF/AHA Heart Failure Guidelines: Executive Summary 2. Measurement of BNP or NT-proBNP and/or cardiac troponin is useful for establishing prognosis or disease severity in acutely decompensated HF (96,99 106). (Level of Evidence: A) CLASS IIb 1. The usefulness of BNP- or NT-proBNPLguided therapy for acutely decompensated HF is not well established (107,108). (Level of Evidence: C) 2. Measurement of other clinically available tests such as biomarkers of myocardial injury or brosis may be consid- ered for additive risk strati cation in patients with acutely decompensated HF (96,101,104,105,109 115). (Level of Evidence: A) 5.4. 